Rajendran Arunagiri

Nov 19, 2024 | pharmaceuticalonline.com | Rajendran Arunagiri

By Rajendran (Raj) Arunagiri When a drug is consumed orally, in most cases the drug/API needs to be delivered into the small intestine. However, the drug needs to pass through the acidic stomach environment before getting to the intestine. Enteric coatings play a pivotal role in modern pharmaceuticals, enabling the effective delivery of medications that would otherwise be compromised by the harsh conditions of the stomach.

May 3, 2024 | cellandgene.com | Zeb Khan |Takehiro Okumura |Erich Bozenhardt |Rajendran Arunagiri

Hello Cell & Gene readers,I'm happy to bring you April's most-clicked articles. Enjoy!Erin Harris, editor in chief Follow me on XAPRIL'S BEST FEATURED EDITORIALWhen Does GMP Matter In Non-GMP Settings? Would you ever need to follow GMP standards in workspaces where GMP is not required or possible? This article digs into why, when, and how to follow the principles of GMP.

Apr 18, 2024 | pharmaceuticalonline.com | Rajendran Arunagiri

Guest Column | April 18, 2024 By Rajendran (Raj) Arunagiri The EU regularly evaluates the safety of all food and consumer products, including titanium dioxide (TiO2) used as a food additive and pharmaceutical excipient. Food-grade TiO2, which is commonly used as a whitening and brightening agent in various food products like chewing gum, mayonnaise, candies, and chocolates, is identified and labeled as E171.

Apr 16, 2024 | drugdiscoveryonline.com | Rajendran Arunagiri

On Feb. 6, 2024, new legislation was introduced in the House of Representatives: the FDA Modernization Act 3.0. It aims to reduce and replace the use of animals in nonclinical research, improve predictivity of nonclinical testing, and potentially reduce drug development times. This article shares an overview. Note that the proposed legislation would still need to go through its course of passing the House and Senate and being signed by the president before becoming a law.

Mar 26, 2024 | laboratorynetwork.com | Erika Roberts |Rajendran Arunagiri

The proposed FDA regulation for laboratory developed tests marks a significant step toward the FDA trying to standardize oversight for these diagnostic tools. As the FDA seeks public input, it is a hot topic as stakeholders grapple with the implications of increased regulatory scrutiny, debating its impact on patient access, innovation, and the overall landscape of diagnostic testing in the U.S.On Feb.